A German court on Tuesday invalidated a CureVac patent that was part of the biotech’s ongoing fight with BioNTech over the mRNA technology used in Covid-19 vaccines.
Had CureVac’s claims been upheld, the biotech could have been in a position to receive a fraction of BioNTech’s Covid-19 vaccine revenues. Instead, Tuesday’s announcement about the German Federal Patent Court’s decision sent CureVac’s shares $CVAC down 25%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.